SEC 13F Intelligence

Managers / Q1 2025 · view latest →

Propel Bio Management, LLC

CIK 0001969764 · 11620 WILSHIRE BLVD.,, SUITE 350, LOS ANGELES, CA, 90025 · 908-507-9629

Reported Value
$86M
Q1 2025
Positions
18
Filings on Record
10
2019–present window
Filed
May 15, 2025
original filing

Summary

Propel Bio Management, LLC reported $86M in U.S.-listed holdings across 18 positions for Q1 2025.

The portfolio is heavily concentrated: PAGPEUR alone accounts for 31.6% of reported value.

Compared with Q4 2024, the fund opened 2 new positions and exited 5.

Portfolio Metrics

Turnover
+9.2%
vs prior filed quarter
Top-10 Concentration
+91.7%
share of reported value
Largest Position
+31.6%
Plains GP Holdings LP Cl
New / Exited
2 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’23: $121MQ4 ’23Q1 ’24: $172MQ2 ’24: $154MQ2 ’24Q3 ’24: $172MQ4 ’24: $101MQ4 ’24Q1 ’25: $86MQ2 ’25: $82MQ2 ’25Q3 ’25: $100MQ4 ’25: $117MQ4 ’25Q1 ’26: $159Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 98.3%Other: 1.7%
  • Common Stock · 98.3% · $85M
  • Other · 1.7% · $2M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MISTMILESTONE PHARMACEUTICALSNEW+1.45M1.45M+$1M$1M
CMPXCOMPASS THERAPEUTICS INCNEW+228.3K228.3K+$433,802$433,802
MAAT PHARMA SACAADDED+163.3K166.4K+$1M$1M
DCTHDELCATH SYSTEMS INCADDED+160.6K177.6K+$2M$2M
ARDXARDELYX INCSOLD OUT−950.9K0−$5M$0
KYMRKYMERA THERAPEUTICS INCSOLD OUT−56.4K0−$2M$0
KURAKURA ONCOLOGY INCSOLD OUT−130.0K0−$1M$0
JSPRJASPER THERAPEUTICS INCSOLD OUT−20.0K0−$427,600$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2025

18 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1PAGPEURPLAINS GP HOLDINGS LP-CLhistory →COMM31.57%$27M1.27M
2MDGLMADRIGAL PHARMACEUTICALShistory →COMM11.56%$10M30.0K
3AKROAKERO THERAPEUTICS INChistory →COMM10.76%$9M228.9K
4PHATPHATHOM PHARMACEUTICALS Ihistory →COMM8.27%$7M1.13M
5SP4PACHIEVE LIFE SCIENCES INChistory →COMM7.61%$7M2.45M
6APLTAPPLIED THERAPEUTICS INChistory →COMM6.41%$6M11.29M
7RNAGBPAVIDITY BIOSCIENCES INChistory →COMM6.12%$5M178.5K
8ABEOABEONA THERAPEUTICS INChistory →COMM3.45%$3M624.0K
9TCRXTSCAN THERAPEUTICS INChistory →COMM3.35%$3M2.09M
10DCTHDELCATH SYSTEMS INChistory →COMM2.63%$2M177.6K
11SNDXSYNDAX PHARMACEUTICALS INhistory →COMM2.62%$2M183.3K
12ZVRAZEVRA THERAPEUTICS INChistory →COMM1.57%$1M179.9K
13MISTMILESTONE PHARMACEUTICALShistory →COMM1.35%$1M1.45M
14MAAT PHARMA SACACOMM1.21%$1M166.4K
15CMPXCOMPASS THERAPEUTICS INCCOMM0.50%$433,802228.3K
16ATHIRA PHARMA INCCOMM0.49%$425,2961.49M
1772CEIGER BIOPHARMACEUTICALSCOMM0.49%$423,000146.4K
18CHINOOK THERAPEUTICSCOMM0.04%$38,50079.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$159M38May 14, 202613F-HRchanges · EDGAR ↗
Q4 2025$117M20Feb 11, 202613F-HRchanges · EDGAR ↗
Q3 2025$100M16Nov 12, 202513F-HRchanges · EDGAR ↗
Q2 2025$82M16Aug 13, 202513F-HRchanges · EDGAR ↗
Q1 2025$86M18May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$101M21Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$172M21Nov 13, 202413F-HRchanges · EDGAR ↗
Q2 2024$154M25Aug 12, 202413F-HRchanges · EDGAR ↗
Q1 2024$172M29May 13, 202413F-HRchanges · EDGAR ↗
Q4 2023$121M34Feb 14, 202413F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • Simplify Asset Management Inc.028-20937

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.